LATUDA 40mg Price

Overview

Welcome to Dwaey, specifically on LATUDA 40mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Lurasidone HCl.
LATUDA 40mg is available in the market in concentration 37mg/Tablet and in the form of Tablets/Film-coated.

MEDIUS AG is the producer of LATUDA 40mg and it is imported from SWITZERLAND, The most popular alternatives of LATUDA 40mg are listed downward .

Mode Of Action

Partial agonist at serotonin 5-HT 1A receptors, and antagonist at dopamine D 2 and serotonin 5-HT 2A receptors.

Indication

• Schizophrenia & bipolar depression.

Precaution

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack). Neuroleptic malignant syndrome: Manage with immediate discontinuation and close monitoring. Tardive dyskinesia: Discontinue if clinically appropriate. Metabolic changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. Hyperglycemia and diabetes mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics. Weight Gain: Gain in body weight has been observed. Monitor weight. Hyperprolactinemia: Prolactin elevations may occur. Leukopenia, neutropenia and agranulocytosis: Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing Lurasidone if a clinically significant decline in WBC occurs in the absence of other causative factors. Orthostatic hypotension and syncope: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment. In patients with known cardiovascularor cerebrovascular disease, and in antipsychotic-naïve patients, consider a lower starting dose and slower titration. Lactation: Unknown whether drug is distributed in breast milk; use caution

Side Effects

• >10% Somnolence
• dose related (22%)
• Akathisia
• dose related (15%)
• Fasting glucose increased (10-14%)
• Nausea (12%)
• Parkinsonism (11%) 1-10% Vomiting (8%)
• Dyspepsia (8%)
• Anxiety (8%)
• Agitation (6%)
• Anxiety (6%)
• Dystonia (5%)
• Dizziness (5%)
• Fatigue (4%)
• Back pain (4%)
• Restlessness (3%)
• Salivary hypersecretion (2%)

Contra indication

Hypersensitivity. Concurrent administration of strong CYP3A4 inhibitors (eg, Ketoconazole). Concurrent administration of strong CYP3A4 inducers (eg, Rifampin). Dementia-related psychosis.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.